Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 4
2011 3
2012 2
2013 2
2014 5
2015 3
2016 6
2017 2
2018 7
2019 5
2020 5
2021 3
2022 4
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Hematological Neoplasms with Eosinophilia.
Morales-Camacho RM, Caballero-Velázquez T, Borrero JJ, Bernal R, Prats-Martín C. Morales-Camacho RM, et al. Among authors: caballero velazquez t. Cancers (Basel). 2024 Jan 12;16(2):337. doi: 10.3390/cancers16020337. Cancers (Basel). 2024. PMID: 38254826 Free PMC article. Review.
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.
García-Calderón CB, Sierro-Martínez B, García-Guerrero E, Sanoja-Flores L, Muñoz-García R, Ruiz-Maldonado V, Jimenez-Leon MR, Delgado-Serrano J, Molinos-Quintana Á, Guijarro-Albaladejo B, Carrasco-Brocal I, Lucena JM, García-Lozano JR, Blázquez-Goñi C, Reguera-Ortega JL, González-Escribano MF, Reinoso-Segura M, Briones J, Pérez-Simón JA, Caballero-Velázquez T. García-Calderón CB, et al. Among authors: caballero velazquez t. Front Immunol. 2023 Apr 14;14:1152498. doi: 10.3389/fimmu.2023.1152498. eCollection 2023. Front Immunol. 2023. PMID: 37122702 Free PMC article.
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.
Rodríguez-Arbolí E, Lee CJ, Caballero-Velázquez T, Martínez C, García-Calderón C, Jiménez-León MR, Bermúdez-Rodríguez MA, López-Corral L, Triguero A, Onstad L, Horwitz ME, Sarantopoulos S, Lee SJ, Pérez-Simón JA. Rodríguez-Arbolí E, et al. Among authors: caballero velazquez t. Clin Cancer Res. 2023 Oct 13;29(20):4057-4067. doi: 10.1158/1078-0432.CCR-23-0666. Clin Cancer Res. 2023. PMID: 37698881
Multiple erythrophagocytosis by erythroid blasts in acute myeloid leukemia with BCR-ABL1.
Mellado-Gázquez Á, Gómez-Núñez MR, Jurado-Herrera S, Prats-Martín C, Caballero-Velázquez T, Morales-Camacho RM. Mellado-Gázquez Á, et al. Among authors: caballero velazquez t. Ann Hematol. 2022 Jun;101(6):1375-1377. doi: 10.1007/s00277-021-04742-2. Epub 2022 Jan 27. Ann Hematol. 2022. PMID: 35083526 No abstract available.
Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S, Pérez-Simón JA. Molinos-Quintana Á, et al. Among authors: caballero velazquez t. Front Immunol. 2024 Jan 16;14:1280580. doi: 10.3389/fimmu.2023.1280580. eCollection 2023. Front Immunol. 2024. PMID: 38292483 Free PMC article.
Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.
Rodríguez-Gil A, Escamilla-Gómez V, Nufer M, Andújar-Sánchez F, Lopes-Ramos T, Bejarano-García JA, García-Guerrero E, Calderón-Cabrera C, Caballero-Velázquez T, García-Calderón CB, Hernández-Díaz P, Reguera-Ortega JL, Rodríguez-Torres N, Martínez-Cibrián N, Rodríguez-Barbosa JI, Villadiego J, Pérez-Simón JA. Rodríguez-Gil A, et al. Among authors: caballero velazquez t. Sci Rep. 2022 May 19;12(1):8348. doi: 10.1038/s41598-022-12407-x. Sci Rep. 2022. PMID: 35589917 Free PMC article.
Limbus damage in ocular graft-versus-host disease.
Pérez RL, Pérez-Simón JA, Caballero-Velazquez T, Flores T, Carrancio S, Herrero C, Blanco B, Gutierrez-Cosio S, Cañete-Campos C, Cruz González F, San-Miguel JF, Hernández-Galilea E, Sánchez-Abarca I. Pérez RL, et al. Among authors: caballero velazquez t. Biol Blood Marrow Transplant. 2011 Feb;17(2):270-3. doi: 10.1016/j.bbmt.2010.08.008. Epub 2010 Aug 26. Biol Blood Marrow Transplant. 2011. PMID: 20800691 Free article.
Genotoxicity of tetrahydrofolic acid to hematopoietic stem and progenitor cells.
García-Calderón CB, Bejarano-García JA, Tinoco-Gago I, Castro MJ, Moreno-Gordillo P, Piruat JI, Caballero-Velázquez T, Pérez-Simón JA, Rosado IV. García-Calderón CB, et al. Among authors: caballero velazquez t. Cell Death Differ. 2018 Nov;25(11):1967-1979. doi: 10.1038/s41418-018-0089-4. Epub 2018 Mar 6. Cell Death Differ. 2018. PMID: 29511342 Free PMC article.
Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease.
Ramos TL, García-Guerrero E, Caballero-Velázquez T, Rodríguez-Gil A, Caracuel-García R, Nufer M, Robles-Frías MJ, Barbado MV, Pérez-Simón JA. Ramos TL, et al. Among authors: caballero velazquez t. Bone Marrow Transplant. 2021 Dec;56(12):3049-3058. doi: 10.1038/s41409-021-01452-1. Epub 2021 Sep 23. Bone Marrow Transplant. 2021. PMID: 34556806 Free PMC article.
52 results